Suraksha Diagno.

Market Cap: Small Cap
Industry: Healthcare Services
ISIN: INE877V01027
NSEID: SURAKSHA
BSEID: 544293

INR

280.50

-0.15 (-0.05%)

BSENSE

Dec 05

BSE+NSE Vol: 7.22 k

{
  "main_header": {
    "sid": 10039467,
    "name": "Suraksha Diagno.",
    "stock_name": "Suraksha Diagno.",
    "full_name": "Suraksha Diagnostic Ltd",
    "name_url": "stocks-analysis/suraksha-diagno",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "280.50",
    "chg": -0.15,
    "chgp": "-0.05%",
    "dir": -1,
    "prev_price": "280.65",
    "mcapval": "1,460.87 Cr",
    "mcap": "Small Cap",
    "scripcode": 544293,
    "symbol": "SURAKSHA",
    "ind_name": "Healthcare Services",
    "ind_code": 94,
    "indexname": "",
    "isin": "INE877V01027",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "7.22 k",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/suraksha-diagno-10039467-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Suraksha Diagno. Sees Revision in Market Evaluation Amidst Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/suraksha-diagno-upgraded-from-sell-to-hold-by-marketsmojo-on-11-aug-2025-3736848",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SurakshaDiagno_mojoScore_3736848.png",
        "date": "2025-11-29 17:52:21",
        "description": "Suraksha Diagno., a small-cap player in the Healthcare Services sector, has recently undergone a revision in its market evaluation metrics, reflecting a nuanced shift in its financial and technical outlook. This adjustment highlights evolving perspectives on the company’s operational quality, valuation, financial trends, and technical positioning amid a challenging market environment."
      },
      {
        "title": "Why is Suraksha Diagno. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-suraksha-diagno-fallingrising-3730060",
        "imagepath": "",
        "date": "2025-11-26 01:33:32",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Comparison</strong></p>\n<p>Suraksha Diagnostic’s shares have experienced a notable decline in recent trading sessions, with the stock falling by 3.27% over the last week and 5.60% in the past month. This contrasts sharply with the Sensex, which has recorded modest gains of 0.45% over the same one-month period and 8.25% year-to-date. The stock’s year-to-date performance is particularly concerning, with a steep decline of 22.10%, while the Sensex has advanced by over 8%. This divergence highlights the stock’s relative weakness amid a generally positive market environment.</p>\n<p>Adding to the negative momentum, Suraksha Diagnostic has underperformed its sector by 0.57% on the day, signalling that the stock is facing sector-specific headwinds or investor reserva..."
      },
      {
        "title": "Are Suraksha Diagno. latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-suraksha-diagno-latest-results-good-or-bad-3690601",
        "imagepath": "",
        "date": "2025-11-11 19:44:38",
        "description": "Suraksha Diagnostic's latest financial results for Q2 FY26 present a mixed operational landscape. The company reported net sales of ₹78.73 crores, reflecting a year-on-year growth of 17.95% and a quarter-on-quarter increase of 8.46%. This marks the seventh consecutive quarter of revenue growth, indicating strong demand for its diagnostic services. However, the operational efficiency appears to be under pressure, as evidenced by a decline in net profit to ₹8.99 crores, which represents a year-on-year decrease of 13.06% and a quarter-on-quarter drop of 4.36%.\n\nThe operating margin has contracted significantly, falling to 30.62% from 34.74% in the same quarter last year, indicating a decline of 412 basis points. Similarly, the profit after tax (PAT) margin has decreased to 11.22%, down 400 basis points year-on-year. These margin compressions raise concerns about the sustainability of the company's growth model..."
      },
      {
        "title": "Suraksha Diagnostic Q2 FY26: Margin Pressure Overshadows Revenue Growth",
        "link": "https://www.marketsmojo.com/news/result-analysis/suraksha-diagnostic-q2-fy26-margin-pressure-overshadows-revenue-growth-3686869",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SurakshaDiagnos_quaterlyResult_3686869.png",
        "date": "2025-11-10 19:37:16",
        "description": "Suraksha Diagnostic Limited, a Kolkata-based healthcare diagnostics provider with a market capitalisation of ₹1,669 crores, reported consolidated net profit of ₹8.99 crores for Q2 FY26, declining 4.36% quarter-on-quarter and 13.06% year-on-year. Despite robust revenue growth of 17.95% YoY to ₹78.73 crores, the company witnessed significant margin compression as operating profit margin (excluding other income) contracted to 30.62% from 34.74% in the year-ago quarter. The stock traded at ₹323.90 on November 10, 2025, showing resilience with gains of 10.66% over the past month, though it remains 13.76% lower year-to-date."
      },
      {
        "title": "Why is Suraksha Diagno. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-suraksha-diagno-fallingrising-3642273",
        "imagepath": "",
        "date": "2025-10-24 00:16:25",
        "description": "As of 23-Oct, Suraksha Diagnostic Ltd's stock price is currently at 311.85, reflecting an increase of 1.8, or 0.58%. The stock has been on an upward trend, gaining for the last seven days with a total return of 8.83% during this period. It has outperformed its sector by 2.3% today. Additionally, the stock's performance over the past week shows a return of +5.44%, while it has underperformed over the past month with a return of -1.17%. The company maintains a low Debt to Equity ratio and has demonstrated healthy long-term growth, with operating profit increasing at an annual rate of 89.29%. Furthermore, high institutional holdings at 35.7% suggest strong investor confidence, contributing positively to the stock's recent performance.\n\nIn the broader market context, Suraksha Diagnostic Ltd's short-term performance of +5.44% over the past week significantly outpaces the Sensex, which has only increased by +1.30..."
      },
      {
        "title": "Is Suraksha Diagno. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-suraksha-diagno-overvalued-or-undervalued-3620664",
        "imagepath": "",
        "date": "2025-10-15 08:07:44",
        "description": "As of 14 October 2025, the valuation grade for Suraksha Diagnostics has moved from fair to expensive, indicating a shift in perception regarding its market value. The company is currently considered overvalued. Key ratios highlight this assessment: the PE ratio stands at 45.39, the Price to Book Value is 7.08, and the EV to EBITDA is 18.26, all of which are significantly higher than industry norms.\n\nIn comparison to its peers, Suraksha Diagnostics' PE ratio is notably lower than that of Max Healthcare, which has a PE of 93.68, and higher than Apollo Hospitals, which is valued at 70.7. The PEG ratio for Suraksha is 0.00, suggesting a lack of growth expectations compared to its price, further reinforcing the overvaluation stance. Additionally, the company's stock has underperformed against the Sensex, with a year-to-date return of -22.4% compared to the Sensex's 4.98%, which underscores the potential disconne..."
      },
      {
        "title": "Is Suraksha Diagno. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-suraksha-diagno-overvalued-or-undervalued-3616705",
        "imagepath": "",
        "date": "2025-10-14 08:07:11",
        "description": "As of 13 October 2025, the valuation grade for Suraksha Diagnostics has moved from expensive to fair. The company appears to be fairly valued at this time. Key ratios include a PE Ratio of 44.68, an EV to EBITDA of 17.97, and a ROCE of 23.40%. \n\nIn comparison to its peers, Suraksha Diagnostics has a PE Ratio that is significantly lower than Max Healthcare, which stands at 92.33, and Apollo Hospitals at 70.2, indicating that Suraksha may offer better value relative to these competitors. While the stock has underperformed against the Sensex over the past year, with a year-to-date return of -23.63% compared to the Sensex's 5.36%, the current valuation suggests that it is not overvalued, especially when considering its strong return metrics...."
      },
      {
        "title": "Suraksha Diagnostic Experiences Valuation Grade Change Amidst Market Challenges and Performance Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/suraksha-diagnostics-valuation-grade-changes-from-expensive-to-fair-amid-stock-decline-3618284",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/SurakshaDiagnos_valuationdot_3618284.png",
        "date": "2025-10-14 08:02:49",
        "description": "Suraksha Diagnostic, a small-cap healthcare services company, has experienced a valuation adjustment, with its current price at 286.85. Over the past year, it has faced challenges, reflected in a year-to-date return of -23.63%. Key financial metrics indicate solid operational efficiency compared to peers in the sector."
      },
      {
        "title": "Why is Suraksha Diagno. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-suraksha-diagno-fallingrising-3608657",
        "imagepath": "",
        "date": "2025-10-10 00:23:58",
        "description": "As of 09-Oct, Suraksha Diagnostic Ltd is currently priced at 294.75, reflecting a decline of 0.95, or 0.32%. The stock has underperformed its sector today by 0.89%, and it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Over the past week, the stock has decreased by 0.92%, and it has seen a more significant drop of 3.68% over the past month. Additionally, the delivery volume has fallen by 53.41% compared to the 5-day average, indicating a decrease in investor participation. Despite having a low debt-to-equity ratio and healthy long-term growth in operating profit, the stock's recent performance suggests a lack of confidence among investors.\n\nIn the broader market context, the Sensex has increased by 1.47% over the past week and 1.32% over the past month, contrasting sharply with Suraksha Diagnostic's negative returns. The stock's year-to-date performance shows a decline of ..."
      }
    ],
    "total": 86,
    "sid": "10039467",
    "stock_news_url": "https://www.marketsmojo.com/news/suraksha-diagnostic-10039467"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "02-Dec-2025",
      "details": "Intimation of Schedule of Analysts / Institutional Investors / Organisations meet",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
      "datetime": "14-Nov-2025",
      "details": "Please find the enclosed transcript of the Earnings Call held on Tuesday 11 November 2025",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "11-Nov-2025",
      "details": "Newspaper publication of unaudited (standalone and consolidated) financial results of the Company for the quarter and six months ended 30 September 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Suraksha Diagno. Sees Revision in Market Evaluation Amidst Mixed Financial Signals

2025-11-29 17:52:21

Suraksha Diagno., a small-cap player in the Healthcare Services sector, has recently undergone a revision in its market evaluation metrics, reflecting a nuanced shift in its financial and technical outlook. This adjustment highlights evolving perspectives on the company’s operational quality, valuation, financial trends, and technical positioning amid a challenging market environment.

Why is Suraksha Diagno. falling/rising?

2025-11-26 01:33:32

Recent Price Movement and Market Comparison

Suraksha Diagnostic’s shares have experienced a notable decline in recent trading sessions, with the stock falling by 3.27% over the last week and 5.60% in the past month. This contrasts sharply with the Sensex, which has recorded modest gains of 0.45% over the same one-month period and 8.25% year-to-date. The stock’s year-to-date performance is particularly concerning, with a steep decline of 22.10%, while the Sensex has advanced by over 8%. This divergence highlights the stock’s relative weakness amid a generally positive market environment.

Adding to the negative momentum, Suraksha Diagnostic has underperformed its sector by 0.57% on the day, signalling that the stock is facing sector-specific headwinds or investor reserva...

Are Suraksha Diagno. latest results good or bad?

2025-11-11 19:44:38

Suraksha Diagnostic's latest financial results for Q2 FY26 present a mixed operational landscape. The company reported net sales of ₹78.73 crores, reflecting a year-on-year growth of 17.95% and a quarter-on-quarter increase of 8.46%. This marks the seventh consecutive quarter of revenue growth, indicating strong demand for its diagnostic services. However, the operational efficiency appears to be under pressure, as evidenced by a decline in net profit to ₹8.99 crores, which represents a year-on-year decrease of 13.06% and a quarter-on-quarter drop of 4.36%. The operating margin has contracted significantly, falling to 30.62% from 34.74% in the same quarter last year, indicating a decline of 412 basis points. Similarly, the profit after tax (PAT) margin has decreased to 11.22%, down 400 basis points year-on-year. These margin compressions raise concerns about the sustainability of the company's growth model...

Suraksha Diagnostic Q2 FY26: Margin Pressure Overshadows Revenue Growth

2025-11-10 19:37:16

Suraksha Diagnostic Limited, a Kolkata-based healthcare diagnostics provider with a market capitalisation of ₹1,669 crores, reported consolidated net profit of ₹8.99 crores for Q2 FY26, declining 4.36% quarter-on-quarter and 13.06% year-on-year. Despite robust revenue growth of 17.95% YoY to ₹78.73 crores, the company witnessed significant margin compression as operating profit margin (excluding other income) contracted to 30.62% from 34.74% in the year-ago quarter. The stock traded at ₹323.90 on November 10, 2025, showing resilience with gains of 10.66% over the past month, though it remains 13.76% lower year-to-date.

Why is Suraksha Diagno. falling/rising?

2025-10-24 00:16:25

As of 23-Oct, Suraksha Diagnostic Ltd's stock price is currently at 311.85, reflecting an increase of 1.8, or 0.58%. The stock has been on an upward trend, gaining for the last seven days with a total return of 8.83% during this period. It has outperformed its sector by 2.3% today. Additionally, the stock's performance over the past week shows a return of +5.44%, while it has underperformed over the past month with a return of -1.17%. The company maintains a low Debt to Equity ratio and has demonstrated healthy long-term growth, with operating profit increasing at an annual rate of 89.29%. Furthermore, high institutional holdings at 35.7% suggest strong investor confidence, contributing positively to the stock's recent performance. In the broader market context, Suraksha Diagnostic Ltd's short-term performance of +5.44% over the past week significantly outpaces the Sensex, which has only increased by +1.30...

Is Suraksha Diagno. overvalued or undervalued?

2025-10-15 08:07:44

As of 14 October 2025, the valuation grade for Suraksha Diagnostics has moved from fair to expensive, indicating a shift in perception regarding its market value. The company is currently considered overvalued. Key ratios highlight this assessment: the PE ratio stands at 45.39, the Price to Book Value is 7.08, and the EV to EBITDA is 18.26, all of which are significantly higher than industry norms. In comparison to its peers, Suraksha Diagnostics' PE ratio is notably lower than that of Max Healthcare, which has a PE of 93.68, and higher than Apollo Hospitals, which is valued at 70.7. The PEG ratio for Suraksha is 0.00, suggesting a lack of growth expectations compared to its price, further reinforcing the overvaluation stance. Additionally, the company's stock has underperformed against the Sensex, with a year-to-date return of -22.4% compared to the Sensex's 4.98%, which underscores the potential disconne...

Is Suraksha Diagno. overvalued or undervalued?

2025-10-14 08:07:11

As of 13 October 2025, the valuation grade for Suraksha Diagnostics has moved from expensive to fair. The company appears to be fairly valued at this time. Key ratios include a PE Ratio of 44.68, an EV to EBITDA of 17.97, and a ROCE of 23.40%. In comparison to its peers, Suraksha Diagnostics has a PE Ratio that is significantly lower than Max Healthcare, which stands at 92.33, and Apollo Hospitals at 70.2, indicating that Suraksha may offer better value relative to these competitors. While the stock has underperformed against the Sensex over the past year, with a year-to-date return of -23.63% compared to the Sensex's 5.36%, the current valuation suggests that it is not overvalued, especially when considering its strong return metrics....

Suraksha Diagnostic Experiences Valuation Grade Change Amidst Market Challenges and Performance Metrics

2025-10-14 08:02:49

Suraksha Diagnostic, a small-cap healthcare services company, has experienced a valuation adjustment, with its current price at 286.85. Over the past year, it has faced challenges, reflected in a year-to-date return of -23.63%. Key financial metrics indicate solid operational efficiency compared to peers in the sector.

Why is Suraksha Diagno. falling/rising?

2025-10-10 00:23:58

As of 09-Oct, Suraksha Diagnostic Ltd is currently priced at 294.75, reflecting a decline of 0.95, or 0.32%. The stock has underperformed its sector today by 0.89%, and it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Over the past week, the stock has decreased by 0.92%, and it has seen a more significant drop of 3.68% over the past month. Additionally, the delivery volume has fallen by 53.41% compared to the 5-day average, indicating a decrease in investor participation. Despite having a low debt-to-equity ratio and healthy long-term growth in operating profit, the stock's recent performance suggests a lack of confidence among investors. In the broader market context, the Sensex has increased by 1.47% over the past week and 1.32% over the past month, contrasting sharply with Suraksha Diagnostic's negative returns. The stock's year-to-date performance shows a decline of ...

View All News

Announcement

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

02-Dec-2025 | Source : BSE

Intimation of Schedule of Analysts / Institutional Investors / Organisations meet

Announcement under Regulation 30 (LODR)-Earnings Call Transcript

14-Nov-2025 | Source : BSE

Please find the enclosed transcript of the Earnings Call held on Tuesday 11 November 2025

Announcement under Regulation 30 (LODR)-Newspaper Publication

11-Nov-2025 | Source : BSE

Newspaper publication of unaudited (standalone and consolidated) financial results of the Company for the quarter and six months ended 30 September 2025